Quote:

---

The clinical trial process (including the data misdirection) is a core problem in the development and approval of treatments like leronlimab. An outdated, cruel, ineffective system IMO (e.g., data mining is a dirty word?, a placebo group?, 'relationship with regulators' perceived as a criteria?) that needs to be revamped.

---

My turn to agree.

I find the whole "relationship with the FDA" bit the most galling. The 13D group claim there's an irreparable relationship between the FDA and Cytodyn because of Nader. If so, that "irreparable bit" is entirely on the FDA.

If Nader has a potential cure for cancer but the FDA won't listen because "he puts out too many PRs" then we have a huge problem with the way the FDA operates.

This isn't a private business with a "Right to Refuse Service" sign behind the cash register. This is a federal regulatory organization that is supposed to work for the people. So as long as Nader gets submissions right, any past personal beef should be 100% irrelevant. You don't have to like who you do business with, especially if it could save millions of lives.